PubMed Health⌕ Search

Biomedical subjects

L C Munch

Publications and source records attributed to L C Munch.

25 records · Page 2Linked to original sources

Safety and efficacy of recombinant human erythropoietin in correcting the anemia of patients with chronic renal allograft dysfunction.

Recombinant human erythropoietin (rHuEPO) is effective in correcting anemia in hemodialysis, peritoneal dialysis, and predialysis patients. Limited studies in patients with failing renal allografts suggest a similar efficacy but provide little information concerning benefits, dose requirements, or adverse events. This study examined these considerations in a group of 40 patients (18 men; 22 women) aged 40.3 +/- 13.8 yr with stable, chronic renal allograft failure. All patients had a hemoglobin < 95 g/L and a serum creatinine > 250 mumol/L at baseline. Patients received rHuEPO (50 U/kg sc) three times weekly for 24 wk along with iron po if serum ferritin was < 100 micrograms/L. Mean hemoglobin rose from 78.9 +/- 10.4 to 102.6 +/- 18.4 g/L after 24 wk. Mean rHuEPO dose at 24 wk was 129.8 +/- 81.9 U/kg per week. With oral iron supplementation only, serum ferritin fell throughout the 24 wk, whereas serum iron, transferrin saturation, and total iron-binding capacity remained stable. Quality of life was assessed by use of the general Sickness Impact Profile and the disease-specific Transplant Disease Questionnaire measures at baseline and every 8 wk during rHuEPO therapy. Significant improvement was noted in global Sickness Impact Profile scores and in four of five dimensions of the Transplant Disease Questionnaire. Serious adverse events were infrequent. No change in mean systolic or diastolic blood pressure was noted, although there was a significantly increased need for antihypertensive drugs in 18 patients (P = 0.0002). A significant inverse correlation was noted between baseline renal function and maintenance rHuEPO dose (r = -0.45; P < 0.05). Twelve patients returned to dialysis during the study.(ABSTRACT TRUNCATED AT 250 WORDS)

Aged↗

Enlarged photon-deficient area in expected site of renal allograft on Tc-99m DTPA study. A sign of renal vein thrombosis.

Tc-99m DTPA renal imaging has been routinely used in postrenal transplant evaluation. A patient's Tc-99m DTPA studies after transplantation are presented, showing a large photon-deficient area in the region of the allograft on the third postoperative day. The photon-deficient area is two to three times larger than that seen in the original, functioning allograft on the first postoperative day. Enlarged to a weight of 530 g, the allograft on gross and microscopic examination confirmed renal vein thrombosis. Enlargement of the photon-deficient area at the anatomic site of the allograft indicates a scintigraphic pattern of renal vein occlusion incompatible with a viable allograft.

Adult↗